세계의 알파 메틸도파 시장 보고서(2024년)
Alpha (a) Methyldopa Global Market Report 2024
상품코드 : 1546392
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ₩ 7,231,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ₩ 10,847,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ₩ 14,463,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

알파 메틸도파 시장 규모는 향후 수년간 급성장이 전망됩니다. 2028년에는 CAGR 10.3%로 151억 4,000만 달러로 성장합니다. 예측 기간의 성장은 진단 기술 향상, 공중 보건 캠페인 확대, 연구 자금 증가, 의료 인프라 개발, 고혈압 사례 증가 등 여러 가지 요인에 기인합니다. 이 기간 중 예상되는 주요 동향으로는 약물전달 시스템 발전, 바이오의약품 혁신, 임상시험 방법 개발, 디지털 건강 솔루션 통합, 헬스케어 분야에서의 인공지능 적용 등이 있습니다.

알파 메틸도파 시장은 고혈압 환자 증가로 인해 성장할 것으로 예상됩니다. 알파 메틸도파는 혈액내 특정 화학물질을 낮추고 혈관 이완을 촉진하며 혈압을 낮춤으로써 고혈압을 효과적으로 치료합니다. 예를 들어 심장 재단이 2024년 1월에 보고한 바에 따르면 호주 성인의 약 23%가 고혈압을 앓고 있으며, 남성(25%)이 여성(22%)보다 더 높은 유병률을 보이고 있습니다. 이러한 추세는 알파 메틸도파 수요를 촉진할 것으로 예상됩니다.

알파 메틸도파 시장은 제네릭 의약품에 대한 선호도가 높아짐에 따라 확대될 것으로 예상됩니다. 알파 메틸도파는 고혈압 관리에 널리 사용되는 제네릭 의약품으로 특히 임산부와 같은 그룹에 혜택을 제공합니다. 미국 식품의약국은 2023년 제네릭 의약품이 미국 처방약 시장의 약 90%를 차지할 것으로 예상하고 있으며, 이는 영국, 호주, 중국, 독일 등 국가에서도 제네릭 의약품이 널리 채택되고 있음을 반영합니다. 이러한 제네릭 의약품에 대한 선호는 알파 메틸도파 시장을 강화할 것으로 예상됩니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

제5장 세계 시장 규모와 성장

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 합병과 인수

제35장 향후 전망과 잠재적 분석

제36장 부록

KSA
영문 목차

영문목차

Alpha methyldopa, often written as a-methyldopa, is a medication primarily used to manage high blood pressure (hypertension) by affecting the central nervous system. It lowers blood pressure and reduces certain chemicals in the body that narrow blood vessels. Alpha methyldopa is also prescribed to treat specific conditions during pregnancy, such as preeclampsia.

The main types of alpha (a) methyldopa include oral and intravenous formulations. Oral alpha methyldopa is taken by mouth and acts as a central alpha-2 adrenergic agonist to treat high blood pressure. It is available in various purity levels, such as purity >=98% and purity >=99%, and has additional applications in conditions such as parkinsonism and hepatic coma.

The alpha (a) methyldopa market research report is one of a series of new reports from The Business Research Company that provides alpha (a) methyldopa market statistics, including the alpha (a) methyldopa industry's global market size, regional shares, competitors with an alpha (a) methyldopa market share, detailed alpha (a) methyldopa market segments, market trends and opportunities, and any further data you may need to thrive in the alpha (a) methyldopa industry. This alpha (a) methyldopa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The alpha (a) methyldopa market size has grown rapidly in recent years. It will grow from $9.31 billion in 2023 to $10.24 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to several factors, increasing awareness about hypertension, a focus on managing chronic diseases, development of generic versions of medications such as alpha methyldopa, an aging population, and rising rates of obesity.

The alpha (a) methyldopa market size is expected to see rapid growth in the next few years. It will grow to $15.14 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to several factors, improvements in diagnostic techniques, the expansion of public health campaigns, increased research funding, development of healthcare infrastructure, and a rise in hypertension cases. Major trends expected during this period include advancements in drug delivery systems, innovations in biopharmaceuticals, developments in clinical trial methodologies, the integration of digital health solutions, and the application of artificial intelligence in healthcare.

The a-methyldopa market is poised for growth due to increasing cases of hypertension. Hypertension, or high blood pressure, results from factors such as poor diet, lack of physical activity, obesity, and elevated stress levels. a-Methyldopa effectively treats hypertension by lowering specific chemicals in the blood, promoting blood vessel relaxation and reducing blood pressure. For example, the Heart Foundation reported in January 2024 that about 23% of adults in Australia have hypertension, with a higher prevalence among men (25%) than women (22%). This trend is expected to drive demand for a-methyldopa.

The a-methyldopa market is also expected to expand due to the growing preference for generic drugs. Generic medications are cost-effective alternatives to brand-name drugs, offering equivalent quality, performance, and safety. a-Methyldopa, as a widely used generic medication for hypertension management, particularly benefits groups such as pregnant women. The U.S. Food and Drug Administration noted in 2023 that generics constitute approximately 90% of the prescription drug market volume in the U.S., reflecting widespread adoption also seen in countries such as the U.K., Australia, China, and Germany. This preference for generics is anticipated to bolster the a-methyldopa market.

The a-methyldopa market is expected to grow due to rising healthcare expenditure. Healthcare expenditure, encompassing spending on healthcare goods and services, is increasing globally due to aging populations, higher incidence of chronic diseases, and greater demand for healthcare services and medications. For instance, in the UK, healthcare spending rose to $363.44 billion (£280.7 billion) in 2021, with an average expenditure of $5422 (£4,188) per person. This increased funding for healthcare services is set to drive demand for a-methyldopa and other hypertension treatments, underscoring its growth potential in the market.

Major companies operating in the alpha (a) methyldopa market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis International AG, Abbott Laboratories, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Mylan N.V., Bausch Health Companies Inc., Intas Pharmaceuticals Ltd., Apotex Inc., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Laboratoires Confab, Globela Pharma Pvt. Ltd., Pro Doc Ltee, AA Pharma inc., LGM Pharma

North America was the largest region in the a-Methyldopa market in 2023. The regions covered in the alpha (a) methyldopa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the alpha (a) methyldopa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alpha (a) methyldopa market consists of sales of extended-release tablets, and combination tablets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alpha (a) Methyldopa Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alpha (a) methyldopa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for alpha (a) methyldopa ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alpha (a) methyldopa market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Scope

Table of Contents

1. Executive Summary

2. Alpha (a) Methyldopa Market Characteristics

3. Alpha (a) Methyldopa Market Trends And Strategies

4. Alpha (a) Methyldopa Market - Macro Economic Scenario

5. Global Alpha (a) Methyldopa Market Size and Growth

6. Alpha (a) Methyldopa Market Segmentation

7. Alpha (a) Methyldopa Market Regional And Country Analysis

8. Asia-Pacific Alpha (a) Methyldopa Market

9. China Alpha (a) Methyldopa Market

10. India Alpha (a) Methyldopa Market

11. Japan Alpha (a) Methyldopa Market

12. Australia Alpha (a) Methyldopa Market

13. Indonesia Alpha (a) Methyldopa Market

14. South Korea Alpha (a) Methyldopa Market

15. Western Europe Alpha (a) Methyldopa Market

16. UK Alpha (a) Methyldopa Market

17. Germany Alpha (a) Methyldopa Market

18. France Alpha (a) Methyldopa Market

19. Italy Alpha (a) Methyldopa Market

20. Spain Alpha (a) Methyldopa Market

21. Eastern Europe Alpha (a) Methyldopa Market

22. Russia Alpha (a) Methyldopa Market

23. North America Alpha (a) Methyldopa Market

24. USA Alpha (a) Methyldopa Market

25. Canada Alpha (a) Methyldopa Market

26. South America Alpha (a) Methyldopa Market

27. Brazil Alpha (a) Methyldopa Market

28. Middle East Alpha (a) Methyldopa Market

29. Africa Alpha (a) Methyldopa Market

30. Alpha (a) Methyldopa Market Competitive Landscape And Company Profiles

31. Alpha (a) Methyldopa Market Other Major And Innovative Companies

32. Global Alpha (a) Methyldopa Market Competitive Benchmarking

33. Global Alpha (a) Methyldopa Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Alpha (a) Methyldopa Market

35. Alpha (a) Methyldopa Market Future Outlook and Potential Analysis

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기